ArticleNature communications2021
Structural characterization of the microbial enzyme urocanate reductase mediating imidazole propionate production.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- An oral-gut microbial metabolite linksGut microbes · 2026Article
- Cardiovascular-kidney-metabolic syndrome through the lens of gut‑derived uremic toxins.Gut microbes · 2026Review
- Gut microbiota-derived imidazole propionate promotes primary sclerosing cholangitis via p38 signalling.Nature metabolism · 2026Article
- Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.European heart journal · 2026Article
- Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology.Nature communications · 2026Article
- Structural insights into urocanate reductase using room-temperature X-ray crystallography.Acta crystallographica. Section D, Structural biology · 2026Article
- Microbiota-Derived Metabolites in Developmental Programming: Bridging Early-Life Gut Microbiota to Childhood Metabolic Disorders.Current medical science · 2026Review
- Histamine in Diabetic Cardiovascular Complications.Reviews in cardiovascular medicine · 2026Review
- Imidazole propionate ameliorates lipid metabolism in adipocytes to attenuate high-fat diet-induced obesity via PPAR signaling pathway.Lipids in health and disease · 2025Article
- Review
- Gut microbial production of imidazole propionate drives Parkinson's pathologies.Nature communications · 2025Article
- Comparative serum imidazole propionate profiling in colorectal adenoma and cancer by UPLC-MS/MS.BMC gastroenterology · 2025Article
- Is Deuterium Sequestering by Reactive Carbon Atoms an Important Mechanism to Reduce Deuterium Content in Biological Water?FASEB bioAdvances · 2025Review
- Gut Microbial Metabolite Imidazole Propionate Impairs Endothelial Cell Function and Promotes the Development of Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- The Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2025Review
- Gut microbiota-derived imidazole propionate: an emerging target for the prevention and treatment of cardiometabolic diseases.Frontiers in endocrinology · 2025Review
- Kinetics of imidazole propionate from orally delivered histidine in mice and humans.NPJ biofilms and microbiomes · 2024Article
- Anticipatory in silico vaccine designing based on specific antigenic epitopes fromIn silico pharmacology · 2024Article
- Imidazole propionate in type 2 diabetes mellitus and cardiovascular diseases: a mini review.Frontiers in immunology · 2024Review
- Dietary- and host-derived metabolites are used by diverse gut bacteria for anaerobic respiration.Nature microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human microbiome can produce metabolites that modulate insulin signaling. Type 2 diabetes patients have increased circulating concentrations of the microbially produced histidine metabolite, imidazole propionate (ImP) and administration of ImP in mice resulted in impaired glucose tolerance. Interestingly, the fecal microbiota of the patients had increased capacity to produce ImP, which is mediated by the bacterial enzyme urocanate reductase (UrdA). Here, we describe the X-ray structures of the ligand-binding domains of UrdA in four different states, representing the structural transitions along the catalytic reaction pathway of this unexplored enzyme linked to disease in humans. The structures in combination with functional data provide key insights into the mechanism of action of UrdA that open new possibilities for drug development strategies targeting type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.